Richter expands marketing rights for Esmya
Hungarian pharmaceuticals company Gedeon Richter received the exclusive distribution and marketing rights for its innovative product Esmya (ulipristal acetate) for the treatment of uterine myoma in Russia, in other CIS republics and in China under a licensing agreement signed between Richter and HRA Pharma, headquartered in Paris, the two companies announced on Monday.
No financial terms of the agreement were disclosed.
Esmya is the lead product of a product portfolio of Swiss pharmaceutical company PregLem, acquired by Richter in 2010, for the treatment of uterine fibrosis, containing ulipristal acetate, a new chemical entity licensed from HRA Pharma.
Richter announced the acquisition of PregLem, a privately held Swiss pharmaceutical company focusing on the treatment of benign gynaecological conditions in October 2010. As a result of the acquisition Richter procured the distribution and marketing rights for Esmya in the European Union and in North America.
Richter noted that Watson Pharmaceuticals, Inc. received exclusive licensing rights from Richter – PregLem to develop and market EsmyaTM in the USA and Canada on December 16, 2010.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.